Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Operating income | -$58.2M | -$53.0M | -$61.1M | -$23.2M | -$42.8M | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172M |
| Net income | -$57.9M | -$52.0M | -$61.4M | -$23.1M | -$42.5M | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$166M |
| EPS (diluted) | -$2.12 | -$1.90 | -$1.90 | -$3.80 | -$3.57 | -$2.95 | -$1.37 | -$0.84 | -$1.32 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.0M | -$43.8M | -$51.5M | -$22.7M | -$42.2M | -$42.1M | -$27.6M | -$33.5M | -$70.8M | -$113M |
| Capital expenditures | $660K | $55.0K | $108K | $83.0K | $62.0K | $333K | $100K | $164K | $515K | $91.0K |
| Free cash flow | -$52.6M | -$43.8M | -$51.6M | -$22.8M | -$42.3M | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32.4M | $40.8M | $49.3M | $1.01M | $68.1M | $70.1M | $26.8M | $26.7M | $33.2M | $85.4M |
| Total assets | $132M | $106M | $122M | $5.20M | $105M | $78.7M | $126M | $95.9M | $200M | $146M |
| Total liabilities | $9.89M | $27.3M | $28.5M | $5.89M | $15.0M | $14.3M | $15.5M | $14.2M | $28.4M | $67.8M |
| Long-term debt | $3.18M | $20.0M | $20.0M | $14.5M | — | — | — | — | — | — |
| Shareholders' equity | $122M | $78.2M | $2.91M | -$694K | $89.7M | $64.4M | $111M | $81.7M | $172M | $78.1M |
| Retained earnings | -$238M | -$290M | -$351M | -$23.1M | -$65.6M | -$116M | -$152M | -$189M | -$269M | -$435M |
| Shares (wtd avg diluted) | 27.3M | 27.5M | 37.3M | 6.09M | 15.4M | 17.7M | 43.3M | 43.9M | 63.8M | 83.1M |
Every figure is extracted from Larimar Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.